Bosutinib in the treatment of chronic myelogenous leukemia


MUDr. Petra Bělohlávková, Ph.D.

IV. interní hematologická klinika FN a LF UK Hradec Králové



In recent years, significant progress has been made in the treatment of chronic myelogenous leukemia, which has led to the discovery of tyrosine kinase inhibitors. The younger representatives of this drug group include bosutinib, which is used in cases of development of resistance or severe toxicity to previous tyrosine kinase inhibitors (imatinib, nilotinib, dasatinib). Therefore bosutinib is most commonly used as a 3rd or higher treatment line for chronic myelogenous leukemia. Bosutinib has very different side effects, with the most common side effect being diarrhea. Other side effects include elevations of liver tests, rash or myelosuppression. Conversely, with electrolyte abnormalities or cardiovascular events, we rarely see bosutinib treatment.



bosutinib, chronic myelogenous leukemia, treatment



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...